Key Points
- Insider Roberto Vieira sold 296 Corcept Therapeutics shares at an average price of $100.82, generating approximately $29,843 and reducing his position by 6.98%. He had also sold 58,333 shares earlier in September for about $6.46 million.
- Corcept reported quarterly revenue of $256.15 million, up 31.7% year over year, and adjusted earnings of $0.36 per share, significantly above the $0.02 consensus estimate.
- Analysts maintain a generally positive outlook, with an average “Moderate Buy” rating and a $138.17 consensus price target versus the reported share price of $110.29. Institutional investors own approximately 93.61% of the stock.
Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) insider Roberto Vieira sold 296 shares of the business's stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $100.82, for a total value of $29,842.72. Following the completion of the sale, the insider directly owned 3,946 shares in the company, valued at $397,835.72. This represents a 6.98% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.
Roberto Wandenkolk Vieira also recently made the following trade(s):
- On Wednesday, September 2nd, Roberto Vieira sold 58,333 shares of Corcept Therapeutics stock. The shares were sold at an average price of $110.76, for a total value of $6,460,963.08.
Corcept Therapeutics Stock Down 4.0%
NASDAQ:CORT opened at $110.29 on Friday. The business's 50-day moving average price is $108.56 and its 200 day moving average price is $75.21. Corcept Therapeutics Incorporated has a 52-week low of $28.66 and a 52-week high of $126.38. The firm has a market cap of $11.92 billion, a P/E ratio of 262.60 and a beta of 0.45.
Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last released its earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 EPS for the quarter, beating the consensus estimate of $0.02 by $0.34. The business had revenue of $256.15 million during the quarter, compared to analyst estimates of $221.15 million. Corcept Therapeutics had a net margin of 6.52% and a return on equity of 8.26%. The business's quarterly revenue was up 31.7% on a year-over-year basis. During the same period in the prior year, the business earned $0.29 earnings per share. Sell-side analysts expect that Corcept Therapeutics Incorporated will post 1.86 EPS for the current year.
Hedge Funds Weigh In On Corcept Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. State of Wyoming boosted its position in shares of Corcept Therapeutics by 29.5% in the first quarter. State of Wyoming now owns 816 shares of the biotechnology company's stock worth $33,000 after buying an additional 186 shares during the period. Sequoia Financial Advisors LLC raised its position in Corcept Therapeutics by 3.7% during the fourth quarter. Sequoia Financial Advisors LLC now owns 6,904 shares of the biotechnology company's stock valued at $240,000 after buying an additional 247 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Corcept Therapeutics during the second quarter valued at $27,000. Campbell Newman Asset Management Inc. lifted its stake in Corcept Therapeutics by 1.9% in the 1st quarter. Campbell Newman Asset Management Inc. now owns 17,251 shares of the biotechnology company's stock worth $695,000 after acquiring an additional 320 shares in the last quarter. Finally, Gould Capital LLC lifted its stake in Corcept Therapeutics by 66.7% in the 1st quarter. Gould Capital LLC now owns 1,000 shares of the biotechnology company's stock worth $40,000 after acquiring an additional 400 shares in the last quarter. 93.61% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of equities analysts recently issued reports on CORT shares. Piper Sandler restated an "overweight" rating and issued a $165.00 target price (up from $88.00) on shares of Corcept Therapeutics in a report on Thursday, July 30th. UBS Group set a $135.00 target price on Corcept Therapeutics in a report on Thursday, May 28th. Weiss Ratings lowered Corcept Therapeutics from a "hold (c)" rating to a "hold (c-)" rating in a research report on Tuesday, September 8th. Truist Financial began coverage on Corcept Therapeutics in a research note on Tuesday, August 18th. They issued a "buy" rating and a $164.00 price target on the stock. Finally, HC Wainwright restated a "buy" rating and set a $165.00 price objective on shares of Corcept Therapeutics in a report on Friday. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Corcept Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $138.17.
Check Out Our Latest Report on Corcept Therapeutics
More Corcept Therapeutics News
Here are the key news stories impacting Corcept Therapeutics this week:
- Positive Sentiment: The European Medicines Agency’s CHMP recommended marketing authorization for Lifyorli (relacorilant) combined with nab-paclitaxel for patients with platinum-resistant ovarian cancer. The recommendation moves Corcept closer to a potential European launch, expanding the commercial opportunity for its oncology pipeline, although final approval by the European Commission is still required. Corcept receives CHMP recommendation
- Positive Sentiment: HC Wainwright reaffirmed its Buy rating and maintained a $165 price target, implying substantial upside from recent trading levels. The bullish view reflects optimism about Lifyorli’s regulatory progress and Corcept’s growth potential.
- Positive Sentiment: Zacks Research raised several longer-term EPS forecasts, including its FY2027 estimate to $2.05 from $1.91 and FY2028 estimate to $4.31 from $4.07. These revisions suggest analysts see improving earnings potential as new products contribute to revenue.
- Neutral Sentiment: Reports highlighted Corcept among companies benefiting from favorable European drug recommendations, reinforcing the visibility of the Lifyorli regulatory milestone. EU drug recommendations
- Negative Sentiment: James Wilson, a Corcept director, sold 10,000 shares for approximately $1.11 million, while another insider previously sold 10,000 shares. Wilson still retains more than 1.06 million shares, limiting the significance of the transaction, but insider selling can weigh on investor sentiment.
- Negative Sentiment: Zacks’ FY2026 EPS estimate of $1.39 is below the broader full-year consensus of $2.02, indicating some concern about near-term earnings expectations despite stronger later-year forecasts.
About Corcept Therapeutics
(
Get Free Report)
Corcept Therapeutics Incorporated is a biopharmaceutical company focused on discovering and developing medicines that modulate the effects of the stress hormone cortisol. The company's research centers on the glucocorticoid receptor, which regulates cortisol activity and may play a role in metabolic, psychiatric, oncologic and other serious diseases.
Corcept's commercial product is Korlym (mifepristone), an oral glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing's syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have not responded adequately to surgery.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
